Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Antibiotic Prophylaxis Before Dental Procedures Can Reduce ONJ Incidence.

Vittorio Montefusco, MD, Francesca Gay, MD, Francesco Spina, MD, Maria Teresa Ambrosini, MD, Massimo Maniezzo, MD, Lucia Farina, MD, Alba Miceli, PhD, Antonio Palumbo, MD, Mario Boccadoro, MD, Paolo Corradini, MD

Blood (2007) 110 (11): 3613.

https://doi.org/10.1182/blood.V110.11.3613.3613

Published: 2007

Journal Articles

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, Patrizia Pregno, Norbert Pescosta, Vincenzo Callea, Clotilde Cangialosi, Tommaso Caravita, Fortunato Morabito, Pellegrino Musto, Sara Bringhen, Patrizia Falco, Ilaria Avonto, Federica Cavallo, Mario Boccadoro, for the Italian Multiple Myeloma Network, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA)

Blood (2006) 109 (7): 2767–2772.

https://doi.org/10.1182/blood-2006-08-042275

Published: 2006

Journal Articles

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Antonio Palumbo, MD, Cecilia Rus, MD, Davide Rossi, MD, Patrizia Pregno, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3560.

https://doi.org/10.1182/blood.V108.11.3560.3560

Published: 2006

Journal Articles

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Antonio Palumbo, MD, Sara Bringhen, MD, Patrizia Falco, MD, Cecilia Rus, MD, Federica Cavallo, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Gabriele Gallone, MD, Tommaso Caravita, MD, Benedetto Bruno, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3562.

https://doi.org/10.1182/blood.V108.11.3562.3562

Published: 2006

Journal Articles

Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial.

Antonio Palumbo, MD, Maria Teresa Ambrosini, MD, Giulia Benevolo, MD, Patrizia Pregno, MD, Norbert Pescosta, MD, Vincenzo Callea, MD, Clotilde Cangialosi, MD, Tommaso Caravita, MD, Fortunato Morabito, MD, Pellegrino Musto, MD, Sara Bringhen, MD, Francesca Gay, MD, Cecilia Rus, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 407.

https://doi.org/10.1182/blood.V108.11.407.407

Published: 2006

Journal Articles

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Antonio Palumbo, MD, Patrizia Falco, MD, Antonietta Falcone, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Nicola Giuliani, MD, Giuseppe Rossi, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Maria Teresa Ambrosini, MD, Jerome Zeldis, MD, Robert Knight, MD, Robin Foà, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2006) 108 (11): 800.

https://doi.org/10.1182/blood.V108.11.800.800

Published: 2006

Journal Articles

Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.

Blood (2005) 106 (11): 779.

https://doi.org/10.1182/blood.V106.11.779.779

Published: 2005

Journal Articles

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Antonio Palumbo, MD, Patrizia Falco, MD, Pellegrino Musto, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Giuseppe Rossi, MD, Nicola Giuliani, MD, Fortunato Morabito, MD, Annalisa Luraschi, MD, Antonietta Falcone, MD, Paola Omedè, PhD, Francesca Gay, MD, Ilaria Avonto, MD, Maria Teresa Ambrosini, MD, Sara Bringhen, MD, Jerome Zeldis, MD, Robert Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2005) 106 (11): 785.

https://doi.org/10.1182/blood.V106.11.785.785

Published: 2005

Journal Articles

Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption.

Daniela Drandi, Marco Ladetto, Sonia Vallet, Loredana Santo, Irene Ricca, Maria Dell’Aquila, Luigia Monitillo, Monica Astolfi, Marina Ruggeri, Maria Teresa Ambrosini, Federica De Marco, Lydia Marino, Barbara Mantoan, Gloria Pagliano, Paola Omedè, Antonio Palumbo, Mario Boccadoro.

Blood (2005) 106 (11): 5088.

https://doi.org/10.1182/blood.V106.11.5088.5088

Published: 2005

Journal Articles

Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.

Antonio Palumbo, MD, Maria Teresa Ambrosini, MD, Patrizia Pregno, MD, Norbert Pescosta, MD, Vincenzo Callea, MD, Clotilde Cangialosi, MD, Tommaso Caravita, MD, Fortunato Morabito, MD, Paola Omedè, PhD, Francesca Gay, MD, Ilaria Avonto, MD, Patrizia Falco, MD, Sara Bringhen, MD, Mario Boccadoro, MD

Blood (2005) 106 (11): 2553.

https://doi.org/10.1182/blood.V106.11.2553.2553

Published: 2005

Journal Articles

Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant.

Antonio Palumbo, MD, Patrizia Falco, MD, Maria Teresa Ambrosini, MD, Tommaso Caravita, MD, Pellegrino Musto, MD, Maria Teresa Petrucci, MD, Patrizia Pregno, MD, Ilaria Avonto, MD, Alessandra Bertola, MD, Sara Bringhen, MD, Federica Cavallo, MD, Giovannino Ciccone, MD, Mario Boccadoro, MD

Blood (2004) 104 (11): 2396.

https://doi.org/10.1182/blood.V104.11.2396.2396

Published: 2004

NARROW

Antibiotic Prophylaxis Before Dental Procedures Can Reduce ONJ Incidence.

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial.

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption.

Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.

Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only